Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of petosemtamab versus investigator's choice monotherapy in previously treated recurrent/metastatic incurable head and neck squamous cell carcinoma
MOH_2024-04-18_013380Phase 3Not yet recruiting
- Sponsor
- Merus
- Start
- Apr 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of petosemtamab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Merus. Primary endpoints: Objective response rate and Overall survival. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
petosemtamab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2024-04-18_013380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-04-18_013380.